4//SEC Filing
PETERSON SCOTT ROBERT 4
Accession 0001209191-18-003647
CIK 0001412067other
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 5:28 PM ET
Size
9.9 KB
Accession
0001209191-18-003647
Insider Transaction Report
Form 4
PETERSON SCOTT ROBERT
Chief Scientific Officer
Transactions
- Exercise/Conversion
Restricted Share Unit (RSU)
2018-01-11−2,825→ 8,475 totalExp: 2027-01-11→ Common Stock (2,825 underlying) - Exercise/Conversion
Common Stock
2018-01-11+2,825→ 4,562 total - Tax Payment
Common Stock
2018-01-11$3.92/sh−923$3,618→ 3,639 total
Footnotes (3)
- [F1]923 shares of the restricted share unit ("RSU") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person.
- [F2]Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs.
- [F3]Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date.
Documents
Issuer
Cascadian Therapeutics, Inc.
CIK 0001412067
Entity typeother
Related Parties
1- filerCIK 0001563986
Filing Metadata
- Form type
- 4
- Filed
- Jan 15, 7:00 PM ET
- Accepted
- Jan 16, 5:28 PM ET
- Size
- 9.9 KB